Biogen (BIIB)
220.83
-3.68 (1.64%)
Upcoming Events
Latest Headlines
Stoke, Biogen share 4-year data on zorevunersen for Dravet syndrome
September 4, 2026 6:00 AM - StreetInsider
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
September 3, 2026 7:30 PM - StreetInsider
Biogen (BIIB) PT Raised to $245 at Piper Sandler
September 3, 2026 7:59 AM - StreetInsider
Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
September 1, 2026 7:30 AM - StreetInsider
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong
September 1, 2026 7:30 AM - StreetInsider
This biotech stock still Wolfe's top pick as multiple catalysts loomh
August 31, 2026 8:00 AM - StreetInsider
Raymond James: 'We now believe that 12 of the top 20 pharma companies have selected Veeva CRM'
August 25, 2026 8:33 AM - StreetInsider
Biogen (BIIB) PT Raised to $260 at RBC Capital, 'Deep Dive Suggests Upcoming Liti SLE Data Could Start I&I Buildout On Right Path'
August 25, 2026 6:36 AM - StreetInsider
Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S.
August 24, 2026 8:01 AM - StreetInsider
Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S.
August 24, 2026 8:01 AM - StreetInsider
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
August 24, 2026 8:00 AM - PR NewsWire
Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
August 20, 2026 4:50 AM - StreetInsider
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
August 13, 2026 9:26 AM - StreetInsider
Wolfe Research Upgrades Biogen (BIIB) to Outperform
August 13, 2026 5:38 AM - StreetInsider
Form 3 BIOGEN INC. For: Aug 03 Filed by: Parini Michael
August 12, 2026 4:51 PM - SEC Filing
Biogen completes acquisition of RayThera in immunology push
August 6, 2026 6:15 PM - StreetInsider
Biogen Completes Acquisition of RayThera Inc.
August 6, 2026 6:15 PM - StreetInsider
Form SCHEDULE 13G/A BIOGEN INC. Filed by: FMR LLC
August 6, 2026 10:18 AM - SEC Filing
Form 4 BIOGEN INC. For: Aug 03 Filed by: Minor Lloyd
August 5, 2026 4:04 PM - SEC Filing
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026 8:00 AM - BizWire
Form 144 BIOGEN INC. Filed by: Minor Lloyd
August 4, 2026 11:23 AM - SEC Filing
Biogen (BIIB) PT Raised to $241 at Mizuho
August 4, 2026 6:39 AM - StreetInsider
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
August 3, 2026 4:01 PM - BizWire
Form 144 BIOGEN INC. Filed by: Minor Lloyd
August 3, 2026 1:02 PM - SEC Filing
Biogen (BIIB) PT Raised to $251 at H.C. Wainwright
July 31, 2026 6:44 AM - StreetInsider
Biogen (BIIB) PT Raised to $240 at UBS
July 30, 2026 9:29 AM - StreetInsider
Biogen (BIIB) PT Raised to $225 at TD Cowen
July 30, 2026 9:10 AM - StreetInsider
Biogen (BIIB) PT Raised to $208 at BMO Capital
July 30, 2026 9:04 AM - StreetInsider
Biogen (BIIB) PT Lowered to $240 at RBC Capital
July 30, 2026 8:32 AM - StreetInsider
Biogen (BIIB) PT Raised to $231 at Morgan Stanley
July 30, 2026 8:13 AM - StreetInsider
Biogen (BIIB) PT Raised to $248 at Canaccord
July 30, 2026 7:20 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Biogen (BIIB)
July 30, 2026 6:42 AM - StreetInsider
Oppenheimer Reiterates Outperform Rating on Biogen (BIIB)
July 29, 2026 1:51 PM - StreetInsider
Biogen (BIIB) call put ratio 1.7 calls to 1 put into quarter results
July 29, 2026 11:15 AM - StreetInsider
Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales
July 29, 2026 6:47 AM - StreetInsider
Form 10-Q BIOGEN INC. For: Jun 30
July 29, 2026 6:37 AM - SEC Filing
Form 8-K BIOGEN INC. For: Jul 29
July 29, 2026 6:10 AM - SEC Filing
Biogen (BIIB) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 EPS Guidance
July 29, 2026 6:07 AM - StreetInsider
Biogen (BIIB) PT Raised to $200 at Barclays
July 29, 2026 5:19 AM - StreetInsider
Biogen (BIIB) call put ratio 1 call to 1 put into quarter results
July 28, 2026 11:15 AM - StreetInsider
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
July 27, 2026 4:01 PM - BizWire
Biogen (BIIB) PT Raised to $280 at Guggenheim
July 21, 2026 6:45 AM - StreetInsider
Biogen (BIIB) PT Lowered to $215 at BofA Securities
July 21, 2026 5:31 AM - StreetInsider
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
July 16, 2026 7:47 AM - PR NewsWire
FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
July 15, 2026 1:29 PM - StreetInsider
Biogen names Michael J. Parini as chief legal officer
July 15, 2026 8:15 AM - StreetInsider
Biogen Appoints Michael J. Parini as Chief Legal Officer
July 15, 2026 8:15 AM - StreetInsider
Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradox
July 14, 2026 11:33 AM - StreetInsider
Real-world Leqembi study shows 82% of Alzheimer's patients stable
July 14, 2026 11:15 AM - StreetInsider
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Tre
July 14, 2026 11:15 AM - PR NewsWire
Biogen Phase 2 data shows diranersen slows Alzheimer's decline
July 14, 2026 9:15 AM - StreetInsider
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
July 14, 2026 9:15 AM - StreetInsider
Piper Sandler Reiterates Overweight Rating on Biogen (BIIB)
July 14, 2026 7:56 AM - StreetInsider
FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
July 13, 2026 5:37 PM - StreetInsider
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
July 13, 2026 5:37 PM - PR NewsWire
Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data
July 13, 2026 8:07 AM - StreetInsider
Stoke Therapeutics names Thomas McCauley as chief scientific officer
July 13, 2026 7:30 AM - StreetInsider
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
July 13, 2026 7:30 AM - BizWire
Leqembi subcutaneous data shows similar efficacy to IV in Alzheimer's
July 13, 2026 5:43 AM - StreetInsider
Truist Securities Upgrades Biogen (BIIB) to Buy
July 13, 2026 5:05 AM - StreetInsider
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference�
July 12, 2026 11:15 AM - PR NewsWire
Biogen (BIIB) PT Lowered to $222 at Morgan Stanley
July 8, 2026 8:07 AM - StreetInsider
Biogen (BIIB) PT Raised to $242 at RBC Capital
July 7, 2026 7:55 AM - StreetInsider
Biogen (BIIB) PT Raised to $157 at HSBC
July 6, 2026 1:34 AM - StreetInsider
Biogen expects $164M R&D charge to hit Q2 2026 earnings
July 1, 2026 4:09 PM - StreetInsider
Form 8-K BIOGEN INC. For: Jul 01
July 1, 2026 4:09 PM - SEC Filing
Stoke Therapeutics completes enrollment in Phase 3 Dravet study
June 30, 2026 8:01 AM - StreetInsider
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
June 30, 2026 8:00 AM - BizWire
Biogen (BIIB) PT Raised to $256 at Needham
June 29, 2026 8:17 AM - StreetInsider
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB
June 29, 2026 8:00 AM - StreetInsider
Biogen to present Phase 2 Alzheimer's drug data at AAIC 2026
June 29, 2026 6:59 AM - StreetInsider
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
June 29, 2026 6:59 AM - StreetInsider
International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
June 22, 2026 9:05 AM - StreetInsider
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026 8:30 AM - StreetInsider
Biogen (BIIB) Reiterated at Overweight by Cantor Fitzgerald: Advancing with BIIB080
June 22, 2026 7:33 AM - StreetInsider
Needham Reiterates Buy Rating on Biogen (BIIB)
June 18, 2026 7:06 AM - StreetInsider
Biogen to acquire RayThera for up to $1 billion
June 17, 2026 6:59 PM - StreetInsider
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
June 17, 2026 6:59 PM - Globe NewsWire
Biogen (BIIB) PT Lowered to $221 at Mizuho
June 15, 2026 6:38 AM - StreetInsider
Form 4 BIOGEN INC. For: Jun 09 Filed by: HAWKINS WILLIAM A
June 11, 2026 5:51 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: SHERWIN STEPHEN A
June 11, 2026 5:48 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Rowinsky Eric K
June 11, 2026 5:46 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Mantas Jesus B
June 11, 2026 5:45 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: LANGER SUSAN
June 11, 2026 5:35 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Patolawala Monish D
June 11, 2026 5:33 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Pangalos Menelas N
June 11, 2026 5:22 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Minor Lloyd
June 11, 2026 5:17 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Freire Maria C
June 11, 2026 5:09 PM - SEC Filing
Form 8-K BIOGEN INC. For: Jun 09
June 10, 2026 4:54 PM - SEC Filing
Form 8-K/A BIOGEN INC. For: May 14
June 10, 2026 4:50 PM - SEC Filing
Needham Upgrades Biogen (BIIB) to Buy
June 8, 2026 6:34 AM - StreetInsider
Full Article List
